Recent 8-K filings for APTN
Highest-materiality recent filing
Adaptin Bio completes reverse merger with private biotech, raises ~$4.76M in private placement
- Merger between Unite Acquisition (shell) and Private Adaptin closed Feb 11, 2025; Private Adaptin becomes wholly owned subsidiary.
- Issued ~3.25M shares to Private Adaptin stockholders; former shell stockholder Lucius Partners retains 3.25M shares.
-
Adaptin Bio opens enrollment in Phase 1 trial of APTN-101 for glioblastoma
Enrollment opened in Phase 1 open-label dose-escalation trial of APTN-101 (BRiTE T-cell engager) for EGFRvIII-positive GBM, at Duke University, up to 15 adult patients.
-
Adaptin Bio shares approved for OTCQB quotation under ticker APTN
Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.
-
Adaptin Bio raises $1M in private placement of 200,000 shares at $5.00 each
Gross proceeds of $1.0 million from sale of 200,000 shares at $5.00 per share in a private placement.
-
Adaptin Bio increases CFO salary to $300k full-time; CDO salary to $150k at 50% commitment
CFO Timothy Maness moved to full-time from 80%; base salary raised from $240k to $300k, retroactive to July 1, 2025.
-
Adaptin Bio files audited FY2024 financials; auditor warns of going concern doubt
Net loss of $3.12M in 2024 vs $0.98M in 2023; no revenue reported.
-
Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial
Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.
-
Adaptin Bio completes reverse merger with private biotech, raises ~$4.76M in private placement
Merger between Unite Acquisition (shell) and Private Adaptin closed Feb 11, 2025; Private Adaptin becomes wholly owned subsidiary.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.55 · Most common event other_material